Single and multiple ion recording techniques for the analysis of diphenylhydantoin and its major metabolite in plasma

Abstract

A method has been developed for single ion monitoring of diphenylhydantoin and its major metabolite 5-(p-hydroxyphenyl)-5-phenylhydantoin in plasma. A plasma extract is reacted with N,O-bis(trimethylsilyl) acetamide and single ion recording is carried out using a gas chromatograph mass spectrometer system. The mass value selected, m/e 254, is common to the TMS ethers of diphenylhydantoin and its principal metabolite 5-(p-hydroxyphenyl)-5-phenylhydantoin. The result indicate that one cause of an adverse reaction to diphenylhydantoin could be a reduced ability to hydroxylate the drugmquantitative methods for the analysis of the drug and its major metabolite have also been developed. Diphenylhydantoin and 5-(p-hydroxyphenyl)-5-phenylhydantoin can be analysed in plasma after addition of deuterium labelled internal standards and conversion to volatile derivatives for mass fragmentographic analysis. Diphenylhydantoin and its internal standard are analysed as the N,N-dimethyl derivative, and the hydroxylated metabolite and its internal standard are converted to a petrimethylsilyl compound by reaction with N,O-bis-(trimethylsilyl)acetamide.

The Bottleneck in the Cancer Biomarker Pipeline and Protein Quantification through Mass Spectrometry–Based Approaches: Current Strategies for Candidate Verification

“…MRM-like approaches have been used since the late 1970s in clinical laboratories for quantification of low molecular weight substances and metabolites (30,31 ). In the late 1990s enzymatically cleaved peptide products were used for quantification of a target protein analyte through MS, as demonstrated by Barr et al (32 ) for apolipoprotein A-I.…”

Human SRMAtlas: A Resource of Targeted Assays to Quantify the Complete Human Proteome

“…In addition, peptide affinity reagents can be used to specifically capture analytes and enhance sensitivity (Anderson et al, 2004). SRM has been applied for decades in the pharmaceutical industry to quantify small molecules (Baty, 1977) and evolved recently into an established technique in the field of proteomics, due to advanced technology and reproducibility across instrument platforms and laboratories (Addona et al, 2009). …”

Multiple reaction monitoring for quantitative biomarker analysis in proteomics and metabolomics☆

“…The first use of the term MRM appeared in a 1978 publication describing chlorine isotope effects [42], however the technique itself had already been applied a year earlier by Baty and Robinson to monitor the plasma levels of the drug phenytoin and its metabolites [41]. Since then, through ever improving triple quadrupole technology, MRM has become the method of choice for low molecular weight chemical analysis.…”

“…For validation of potential biomarkers in clinical samples, the MS-based technique of multiple reaction monitoring (MRM) is now being explored. MRM is not a new technique: it has been employed by small molecule mass spectrometrists for over 30 years and is widely used in drug metabolism studies for quantification of metabolites [41][42][43][44][45][46]. However, the application Table 1 The biomarker development pathway, indicating the nature of the analysis in the three phases of discovery, validation and clinical application.…”